One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

Johnson & Johnson recently rolled out a TV ad that takes aim at a major disparity in dermatology: the fact that people of ...

Skyrizi (risankizumab-rzaa) is a prescription drug that’s used to treat Crohn’s disease, plaque psoriasis, and psoriatic arthritis. Skyrizi can cause side effects that range from mild to serious.

A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis,” published in the November 2024 issue of Dermatology by Ferris et al.

"The approval of Sotyktu represents an exciting day for patients suffering from moderate-to-severe plaque psoriasis who are not satisfied with topical and conventional treatments," said Samit ...

First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement ...

Guselkumab achieved clear or almost clear skin in 74.2% of patients with moderate plaque psoriasis, compared to 12.4% on placebo. The VISIBLE study showed rapid and significant clearance of scalp ...

Tremfya (guselkumab) is a prescription drug that’s used to treat certain autoimmune conditions, including plaque psoriasis. Tremfya can cause side effects that range from mild to serious.